Medullary carcinoma of the breast: a population-based perspective.
Prognostic factors specific to medullary carcinoma of the breast (MCB) are unknown. Our objective was to identify patient and tumor factors predictive of overall survival (OS) in a large cohort of MCB patients. The Surveillance, Epidemiology, and End Results database was used to identify patients with MCB diagnosed from 1988 to 2004. Patient, tumor, and treatment factors were compared by univariate analysis via the Kaplan–Meier method and survival differences detected using the log-rank test. A multivariate Cox proportional hazards model controlled for patient age, race, type of surgery, radiotherapy, tumor size, number of lymph node metastases (LNM), lymph node yield (LNY), estrogen receptor (ER) and progesterone receptor (PR) status, and extent of disease. On univariate analysis of 3,348 patients, factors influencing OS included age, race, tumor size, ER status, type of surgery, radiotherapy, LNM, LNY, and extent of disease (P<0.001). On multivariate analysis, advancing age (P<0.001), black race (P<0.001), regional metastases (P<0.001), distant metastases (P<0.001), increasing tumor size (P<0.001), ER positivity (P=0.003), and increasing LNM (P<0.001) were associated with decreased OS. An OS benefit was seen in PR-positive patients (P=0.002) and in those with increasing LNY (P<0.001). Even among node-negative patients, increasing LNY was associated with improved OS (P<0.001). Tumor size, LNM, regional and distant metastases, PR status, age, and race are important prognostic factors in MCB. ER positivity was associated with decreased OS, which may reflect inaccuracy in diagnosing MCB or a significant biologic variant. The improved OS seen with increasing LNY in node-negative patients suggests MCB may be currently understaged.
Martinez
Steve R
SR
Department of Surgery, University of California Davis, Davis, CA, USA. steve.martinez@ucdmc.ucdavis.edu
Beal
Shannon H
SH
Canter
Robert J
RJ
Chen
Steven L
SL
Khatri
Vijay P
VP
Bold
Richard J
RJ
D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology; D018276:Carcinoma, Medullary / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D018426:SEER Program
Surg Gynecol Obstet. 1983 Dec;157(6):497-9
6648768
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1040-7
15990007
Cancer Res. 2006 May 1;66(9):4636-44
16651414
Clin Cancer Res. 2008 Oct 15;14(20):6625-33
18927304
Cancer. 1988 Jun 15;61(12):2503-10
2835145
Breast Cancer Res Treat. 1990 Oct;16(3):215-29
2085673
Cancer. 2003 Sep 1;98(5):908-17
12942556
Br Med J. 1970 Jul 25;3(5716):181-8
5448777
J Clin Oncol. 2006 Apr 10;24(11):1656-64
16505416
J Surg Oncol. 1995 Oct;60(2):89-94
7564387
Breast Cancer Res Treat. 1989 Oct;14(1):91-9
2605345
Ann Oncol. 2001 Apr;12(4):525-33
11398888
Am J Surg. 2007 Oct;194(4):527-31
17826073
Mod Pathol. 1995 Jan;8(1):31-8
7731939
Cancer. 2002 Jun 1;94(11):2844-54
12115371
Med Oncol. 2010 Dec;27(4):1420-4
20049562
Cancer. 1980 Apr 15;45(8):2001-5
6245787
Am J Surg. 2008 Oct;196(4):495-9
18809050
J Surg Oncol. 1984 Feb;25(2):76-8
6694404
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Cancer. 1977 Oct;40(4):1365-85
907958
J Natl Cancer Inst. 2005 Mar 16;97(6):439-48
15770008